Establishment Labs (ESTA) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
10 Apr, 2026Executive summary
The annual meeting is scheduled for May 22, 2026, to be held virtually, with shareholders of record as of April 2, 2026, eligible to vote on key proposals.
Shareholders will vote on the election of six directors, an advisory say-on-pay vote for executive compensation, and ratification of the external auditor for 2026.
The company reported 2025 revenue of $211.1 million (up 27.2% from 2024), a net loss of $51.1 million (improved from $84.6 million in 2024), and a year-end cash balance of $75.6 million.
Strategic highlights include a new CEO appointment, product launches, and a $25 million term loan facility.
Voting matters and shareholder proposals
Proposals include electing six directors, approving executive compensation on an advisory basis, and ratifying CBIZ CPAs P.C. as the independent auditor for 2026.
The board recommends voting FOR all proposals.
Shareholder proposals for the 2027 meeting must be submitted between January 22 and February 21, 2027.
Board of directors and corporate governance
The board will be reduced to six members after the meeting, with a majority classified as independent.
Board leadership is separated between the Chairman and CEO roles.
Committees include Audit, Compensation, and Nominating & Corporate Governance, all composed of independent directors.
Directors are subject to share ownership requirements and an overboarding policy.
Annual board and committee self-evaluations are conducted.
Latest events from Establishment Labs
- 2025 guidance targets $205–$210M revenue, EBITDA positive, and rapid US-driven growth.ESTA
Investor Day 20259 Jul 2026 - Rapid U.S. growth, premium pricing, and innovation set the stage for market dominance and expansion.ESTA
TD Cowen 46th Annual Health Care Conference8 Jul 2026 - Q4 revenue up 45%, gross margin at 70.5%, and 2026 revenue growth guided above 25%.ESTA
Q4 20258 Jul 2026 - All proposals passed with majority approval and no shareholder questions were raised.ESTA
AGM 202628 May 2026 - Q1 revenue up 45% year-over-year, gross margin at 70.7%, and 2026 guidance raised.ESTA
Q1 20268 May 2026 - Director compensation figures were corrected, and additional equity awards disclosed for consulting roles.ESTA
Proxy filing24 Apr 2026 - Vote on directors, executive pay, and auditor ratification at the May 2026 annual meeting.ESTA
Proxy filing10 Apr 2026 - Q2 revenue rose 18.7% sequentially; FDA approval for Motiva Implants expected soon.ESTA
Q2 20242 Feb 2026 - Innovation, global expansion, and regulatory progress position the company for rapid growth.ESTA
Goldman Sachs 45th Annual Global Healthcare Conference1 Feb 2026